LYTIR

Company · IMRX

Immuneering Corporation

Name as listed on its exchange; filed with the SEC as Immuneering Corp.

Nasdaq's symbol directory lists IMRX on Nasdaq as “Immuneering Corporation - Class A Common Stock”.

In the 12 months to Nov 19, 2026: insiders bought on 3 occasions ($125K); 2 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $125K in total; Insider sales: $0 in total.Jun: Insider purchases $36KNov: Insider purchases $90KDecJanFebMarAprMayJunJulAugSepOctNov$90K
Insider purchases above the line: $125KInsider sales below: $0
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Andrew Gengos, Chief Financial Officer bought on 1 day latest Nov 13, 2026 bought $90K
  2. Brett Matthew Hall, CHIEF SCIENTIFIC OFFICER bought on 1 day latest Jun 15, 2026 bought $25K
  3. Benjamin J. Zeskind, PRESIDENT AND CEO bought on 1 day latest Jun 23, 2026 bought $11K
Every trade (3)
  1. BUYAndrew Gengos, Chief Financial Officer bought Nov 13, 2026 25,000 shares filing $90K
  2. BUYBenjamin J. Zeskind, PRESIDENT AND CEO bought Jun 23, 2026 2,400 shares filing $11K
  3. BUYBrett Matthew Hall, CHIEF SCIENTIFIC OFFICER bought Jun 15, 2026 6,035 shares filing $25K

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Departure or appointment of directors or officers filing Nov 9, 2026
  2. Results of operations and financial condition filing Oct 29, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.